Axomove has successfully raised €4 million in a Series A funding round, co-led by the Fonds Prévention Numérique managed by Bpifrance and Go Capital, alongside Inco Ventures and Faraday Venture Partners. This funding aims to accelerate the commercialization of Axomove’s digital medical device, which is currently the only reimbursed digital rehabilitation solution by the French health insurance system. The company plans to use the funds to enhance its commercial development, expand reimbursement coverage to include musculoskeletal and metabolic diseases, and enrich its technological platform with advanced features such as motion capture and gamification.

The significance of this funding lies in Axomove’s ability to address a pressing public health issue, as one in two adults in France suffers from musculoskeletal disorders. The device has demonstrated measurable clinical benefits, including doubling functional capacities and increasing therapeutic adherence by fivefold. Additionally, it has shown substantial economic impact, reducing absenteeism by half and healthcare costs by a third. These metrics underscore Axomove’s potential to improve patient outcomes while simultaneously enhancing the efficiency of the healthcare system.

The key takeaway from this development is that Axomove’s progress could shift the landscape of digital health interventions in rehabilitation and prevention. By securing institutional investment and expanding its reimbursement framework, Axomove is positioned to become a standard of care in these domains. This could catalyze further research into digital therapeutics, influencing drug development timelines and encouraging the integration of technology in clinical practice for better healthspan outcomes.

Source: globenewswire.com